30/04/2016 20:30:25 1-888-992-3836 (toll free) Free Membership Login

Myriad Genetics News (NASDAQ:MYGN)

DateTimeSource
Headline
04/28/201611:46AMGLOBEMyriad to Announce Fiscal Third-Quarter 2016 Financial Results on May 3
SALT LAKE CITY, April 22, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal third-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, May 3.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee... More...>>
04/14/20167:05AMGLOBEMyriad Genetics Announces Presentations at the 2016 American Association for Cancer Research Annual Meeting
SALT LAKE CITY, April 14, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the company and its scientific collaborators will present two studies at the American Association for Cancer Research annual meeting, April 16-20, in... More...>>
03/30/20167:05AMGLOBEMyriad myRisk® Hereditary Cancer Article in Journal of Clinical Oncology Highlights Importance of Expanding Genetic Testing ...
SALT LAKE CITY, March 30, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, working in collaboration with researchers from the Harvard Medical School, today announced that the Journal of Clinical Oncology has published a paper showing the frequency... More...>>
03/21/20167:05AMGLOBEMyriad Genetics Teams Up with Access Health® to Educate the Public about Hereditary Cancer and Genetic Testing
SALT LAKE CITY, March 21, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, and Access Health®, an educational program focused on health and wellness, today announced that they will air an educational program on hereditary cancer that will appear... More...>>
03/18/20167:05AMGLOBEThe Myriad myRisk® Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations in Patients with Endometrial Canc...
SALT LAKE CITY, March 18, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will present two important new studies at the 2016 Society for Gynecologic Oncology annual meeting in San Diego, Calif.  The data demonstrate the ability... More...>>
03/15/20167:05AMGLOBEMyriad Presents Second Pivotal Validation Study for Its myPath® Melanoma Test
SALT LAKE CITY, March 15, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced the results from the second pivotal clinical validation study for the myPath® Melanoma test at the 2016 USCAP Annual Meeting in Seattle, Wash. “There is... More...>>
03/09/20167:46PMGLOBEMyriad Genetics to Present at the Barclays Capital 2016 Global Healthcare Conference
SALT LAKE CITY, March 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine,  today announced that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the Barclays Capital 2016 Global Healthcare Conference at 2:35 p.m... More...>>
03/09/20167:46PMGLOBEMyriad Advances Proprietary myVision® Variant Classification Tools to a Broader Range of Cancer Risk Genes
SALT LAKE CITY, March 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will present new data on its proprietary variant classification program that is used to classify variants in cancer risk genes.  The study will be... More...>>
02/22/20167:05AMGLOBEMyriad Expands Diagnostic Research Collaboration With TESARO and Merck
SALT LAKE CITY, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced a strategic research collaboration with TESARO and Merck, known as MSD outside the U.S. and Canada, to help identify potential responders to an investigational... More...>>
02/02/20164:05PMGLOBEMyriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results
Total Revenues of $193.3 Million Adjusted Diluted EPS of $0.45 and Diluted EPS of $0.41 Company Maintains Fiscal Year 2016 Revenue Guidance, Raises Fiscal Year 2016 Earnings Guidance and Provides Fiscal Third-Quarter 2016 Financial Guidance SALT LAKE CITY, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN... More...>>
01/21/20164:05PMGLOBEMyriad to Announce Fiscal Second-Quarter 2016 Financial Results on February 2
SALT LAKE CITY, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, Feb. 2.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee... More...>>
01/07/20167:05AMGLOBEMyriad Advances Prostate and Renal Cancer Molecular Diagnostic Tests at the 2016 ASCO Genitourinary Cancers Symposium
SALT LAKE CITY, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data will be highlighted on prostate and renal cancers at the 2016 ASCO Genitourinary Cancers Symposium, January 7-9, in San Francisco, Calif. ... More...>>
01/04/20165:00PMGLOBEMyriad Genetics to Present at the 34th Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 34th annual J.P. Morgan Healthcare Conference at 9:30 a.m. PST (12:30 pm EST) on January 11, 2016, at the Westin St. Francis in San... More...>>
12/10/20157:05AMGLOBEmyChoice HRD(TM) Test Identifies Breast Cancer Patients Likely to Respond to Platinum-Containing Therapies
SALT LAKE CITY, Dec. 10, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data will be presented demonstrating the role of the myChoice HRD companion diagnostic in identifying patients with breast cancer who are likely to... More...>>
12/09/20157:05AMGLOBEMultiple Scientific Presentations at the San Antonio Breast Cancer Symposium Highlight the Clinical Utility of the Myriad myR...
SALT LAKE CITY, Dec. 9, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will highlight three scientific presentations related to its myRisk Hereditary Cancer test at the 2015 San Antonio Breast Cancer Symposium (SABCS) in San... More...>>
12/01/20157:05AMGLOBEUnited States Patent and Trademark Office Grants Patent for Vectra(R) DA
SALT LAKE CITY, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent No. 9,200,324. The patent, which is expected to expire in 2031, provides intellectual... More...>>
11/17/20157:05AMGLOBEMyriad Will Present Eight Studies at the 2015 San Antonio Breast Cancer Symposium
New Data on the myChoice® HRD and myRisk™ Hereditary Cancer Tests Will be Highlighted SALT LAKE CITY, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that it will present eight posters at the 2015 San Antonio... More...>>
11/16/20157:05AMGLOBEMyriad RBM DiscoveryMAP(R) Technology Identifies Novel Biomarkers That May Predict Increased Risk of Cardiovascular Events in...
SALT LAKE CITY, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that its DiscoveryMAP® platform successfully identified combinations of 15 protein biomarkers associated with cardiovascular (CV) events or death in people with pre-diabetes... More...>>
11/07/20157:30PMGLOBECrescendo Bioscience Announces That New Studies With Vectra(R) DA Data Will be Presented at the American College of Rheumatol...
SALT LAKE CITY, Nov. 7, 2015 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra DA to predict treatment response in patients with rheumatoid arthritis (RA) are being presented at the American College of Rheumatology/Association... More...>>
11/07/20159:20AMTMFGenomic Health, Inc. on Path to Profitability
http://www.fool.com/investing/general/2015/11/07/genomic-health-inc-on-path-to-profitability.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V:us D:20160501 00:30:26